Company: LENZ
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001628280-25-016822
Chunk: 57

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: S-3
Chunk 57
---
 employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

• We will advance expenses, including attorneys’ fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the company, subject to limited exceptions.

We have entered into separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the DGCL. We have entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our certificate of incorporation. Our bylaws also permit us to maintain insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have obtained a policy of director’s and officer’s liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of directors and officers for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act.

The underwriting agreement to be filed as Exhibit 1.1 to this registration statement may provide for indemnification by the underwriters of us and our directors and officers for certain liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise.

<div align='center'>II-2</div>

## Item 16. Exhibits
|         |     |                                                                                                                                                     |     | Incorporation by Reference |     |            |     |                |     |           |     |                |
| Exhibit 
 Number  |     | Exhibit Description                                                                                                                                 |     | Form                       |     | File       
 Number     |     | Exhibit Number |     | Filing    
 Date      |     | Filed Herewith |
| 1.1*    |     | Form of Underwriting Agreement                                                                                                                      |     |                            |     |            |     |                |     |           |     |                |
| 1.2     |     | Sales Agreement, datedApril4, 2025, by and between the Registrant and TD Securities (USA)